Cesca Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants

Cesca Therapeutics Announces Pricing of Public Offering of Common Stock and

RANCHO CORDOVA, Calif., June 13, 2014 (GLOBE NEWSWIRE) -- Cesca Therapeutics
Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company,
announced today the pricing of an underwritten public offering of 7,530,000
Units, consisting of an aggregate of 7,530,000 shares of the Company's common
stock and warrants to purchase 2,259,000 shares of the Company's common stock,
at a price of $1.50 per Unit. Each warrant entitles the holder to purchase
0.30 of a share of common stock. The warrants will be exercisable immediately
upon issuance at an exercise price of $1.55 per share and will expire five
years from the date of issuance. The shares of common stock and warrants
comprising the Units are immediately separable. All of the Units in the
offering are being sold by Cesca. The gross proceeds to Cesca from this
offering are expected to be approximately $11.3 million, excluding any future
proceeds from the potential exercise of the warrants and before deducting
underwriting discounts and commissions and other estimated offering expenses
payable by Cesca. The offering is expected to close on or about June 18, 2014,
subject to the satisfaction of customary closing conditions.

Maxim Group LLC is acting as sole book-running manager and H.C. Wainwright &
Co., LLC is acting as a co-manager for the offering.

The Units will be issued by Cesca pursuant to a shelf registration statement
that was previously filed with, and declared effective by, the Securities and
Exchange Commission (SEC). A preliminary prospectus supplement related to the
offering has been filed with the SEC and is available on the SEC's website
located at www.sec.gov. A final prospectus supplement related to the offering
will be filed with the SEC.

This press release does not constitute an offer to sell or a solicitation of
an offer to buy nor shall there be any sale of these securities in any state
or jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such
state or jurisdiction. Any offer, if at all, will be made only by means of a
prospectus supplement and accompanying prospectus forming a part of the
effective registration statement, copies of which may be obtained, when
available, from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY
10174 or via telephone at (800) 724-0761.

About Cesca Therapeutics Inc.

Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the
research, development, and commercialization of autologous cell-based
therapeutics for use in regenerative medicine. We are a leader in developing
and manufacturing automated blood and bone marrow processing systems that
enable the separation, processing and preservation of cell and tissue therapy
products.These include:

  *SurgWerks™ Platform, proprietary stem cell therapy point-of-care kit
    systems for treating vascular and orthopedic indications that integrate
    the following indication specific systems:

       *Cell harvesting
       *Cell processing and selection
       *Cell diagnostics
       *Cell delivery

  *CellWerks^TM Platform, a proprietary stem cell laboratory kit for
    processing target cells used in the treatments of oncological and
    hematological disorders.
  *AXP^® AutoXpress^® Platform (AXP), a proprietary family of automated
    devices that includes the AXP and the MXP^® MarrowXpress^® and companion
    sterile blood processing disposables for harvesting stem cells in closed
    systems. The AXP device is used for the processing of cord blood.
  *The MarrowXpress Platform (MXP), a derivative product of the AXP and its
    accompanying disposable bag set, isolates and concentrates stem cells from
    bone marrow. Self-powered and microprocessor-controlled, the MXP contains
    flow control optical sensors that volume-reduces blood from bone marrow to
    a user defined volume in 30 minutes, while retaining over 90% of the MNCs.
  *The Res-Q™ 60 (Res-Q), a point-of-care system designed for the preparation
    of cell concentrates, including stem cells, from bone marrow aspirates and
    whole blood for platelet rich plasma (PRP).
  *The BioArchive^® System, an automated cryogenic device, used by cord blood
    stem cell banks in more than 30 countries for cryopreserving and archiving
    cord blood stem cell units for transplant.

Forward Looking Statement

This press release contains forward-looking statements. Such forward-looking
statements include but are not limited to that Cesca Therapeutics Inc. will be
able to close it proposed offering of Units. These statements and Cesca
Therapeutics' business involve risks and uncertainties that could cause actual
outcomes to differ materially from those contemplated by the forward-looking
statements. A more complete description of risks that could cause actual
events to differ from the outcomes predicted by Cesca Therapeutics'
forward-looking statements is set forth under the caption "Risk Factors" in
Cesca Therapeutics annual report on Form 10-K and other reports it files with
the Securities and Exchange Commission from time to time, and you should
consider each of those factors when evaluating the forward-looking statements.

CONTACT: Cesca Therapeutics Inc.
         Website: http://www.cescatherapeutics.com
         Contact: Investor Relations
         +1-916-858-5107, or

Cesca Therapeutics Inc. logo
Press spacebar to pause and continue. Press esc to stop.